首页> 外文期刊>Journal of Oncology Practice >Can Patient Comorbidities Be Included in Clinical Performance Measures for Radiation Oncology?
【24h】

Can Patient Comorbidities Be Included in Clinical Performance Measures for Radiation Oncology?

机译:放射肿瘤学的临床表现指标中可以包括患者合并症吗?

获取原文
           

摘要

AbstractACE-27 is predictive of treatment modifications for patients with cancers of the breast, cervix, lung, prostate, and stomach who receive radiation as part of their care. Purpose: Patient comorbidities may affect the applicability of performance measures that are inherent in multidisciplinary cancer treatment guidelines. This article describes the distribution of common comorbid conditions by disease site and by patient and facility characteristics in patients who received radiation therapy as part of treatment for cancer of the breast, cervix, lung, prostate, and stomach, and investigates the association of comorbidities with treatment decisions. Materials and Methods: Stratified two-stage cluster sampling provided a random sample of radiation oncology facilities. Eligible patients were randomly sampled from each participating facility for each disease site, and data were abstracted from medical records. The Adult Comorbidity Evaluation Index (ACE-27) was used to measure comorbid conditions and their severity. National estimates were calculated using SUDAAN statistical software. Results: Multivariable logistic regression models predicted the dependent variable “treatment changed or contraindicated due to comorbidities.” The final model showed that ACE-27 was highly associated with change in treatment for patients with severe or moderate index values compared to those with none or mild (P .001). Two other covariates, age and medical coverage, had no (age) or little (medical coverage) significant contribution to predicting treatment change in the multivariable model. Disease site was associated with treatment change after adjusting for other covariates in the model. Conclusions: ACE-27 is highly predictive of treatment modifications for patients treated for these cancers who receive radiation as part of their care. A standardized tool identifying patients who should be excluded from clinical performance measures allows more accurate use of these measures.
机译:AbstractACE-27可预测乳腺癌,宫颈癌,肺癌,前列腺癌和胃癌患者接受放射治疗的治疗方案。目的:患者合并症可能会影响多学科癌症治疗指南中固有的性能指标的适用性。本文介绍了在乳腺癌,子宫颈癌,肺癌,前列腺癌和胃癌治疗中接受放射治疗的患者中,按疾病部位,患者和设施特征划分的常见合并症分布情况,并研究了合并症与治疗决策。材料和方法:分层的两阶段整群抽样提供了放射肿瘤学设施的随机样本。从每个参与机构针对每个疾病部位随机抽取符合条件的患者,并从病历中提取数据。成人合并症评估指数(ACE-27)用于测量合并症和严重程度。国家估计数是使用SUDAAN统计软件计算的。结果:多变量logistic回归模型预测因变量“由于合并症而改变或禁忌了治疗”。最终模型显示,与无或轻度指标的患者相比,ACE-27与重度或中度指标值的患者的治疗变化高度相关(P <.001)。年龄和医疗覆盖率这两个其他协变量对预测多变量模型中的治疗变化没有(年龄)或几乎没有(医疗覆盖率)有重大贡献。调整模型中的其他协变量后,疾病部位与治疗变化相关。结论:ACE-27可以高度预测接受这些放射治疗的癌症患者的治疗方案。用于识别应从临床表现指标中排除的患者的标准化工具可以更准确地使用这些指标。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号